FDA approves J&J prostate cancer treatment

(Reuters) – The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson’s Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.


Source: Reuters Medical News

U.S. healthcare spending to climb 5.3 percent in 2018: agency

WASHINGTON (Reuters) – United States health spending is projected to rise 5.3 percent in 2018, reflecting rising prices of medical goods and services and higher Medicaid costs, a U.S. government health agency said on Wednesday, an upward trend it forecasts for the next decade.


Source: Reuters Medical News